The U.S. Agency for Healthcare Research and Quality (AHRQ) recently released a draft review on the evidence on discontinuation of disease-modifying therapies. Shocked by the apparent lack of expertise in the first draft, MS researchers and advocacy groups sent in a wave of comments chastising the AHRQ for the perceived shoddiness of the report.